Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms

Cancer Research

Volumn 68, Issue 1, 2008, Pages 152-161

  Chakraborty, Goutam ^a   Jain, Shalini ^a   Kundu, Gopal C ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 6; BREAST TUMOR KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEUROPILIN 1; OSTEOPONTIN; SMALL INTERFERING RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ACTIVATING TRANSCRIPTION FACTOR 4; ATF4 PROTEIN, HUMAN; NF KAPPA B KINASE; NF-KAPPA B KINASE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PTK6 PROTEIN, HUMAN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; CELL MOTILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TUMOR GROWTH; ANIMAL; BREAST TUMOR; CELL MOTION; DRUG EFFECT; FEMALE; METABOLISM; MOUSE; MOUSE STRAIN; NEOVASCULARIZATION (PATHOLOGY); PARACRINE SIGNALING; PATHOLOGY; PHYSIOLOGY; VASCULARIZATION;

ACTIVATING TRANSCRIPTION FACTOR 4; ANIMALS; AUTOCRINE COMMUNICATION; BREAST NEOPLASMS; CELL MOVEMENT; ENDOTHELIAL CELLS; FEMALE; HUMANS; MICE; MICE, INBRED STRAINS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NEUROPILIN-1; NF-KAPPA B; OSTEOPONTIN; PARACRINE COMMUNICATION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 39149110606     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2126     Document Type: Article

References (46)

1. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-4.
2. Rifkin DB, Moscatelli D. Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol 1989;109:1-6.
3. Nicosia RF, Nicosia SV, Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol 1994;145:1023-9.
4. Gleave ME, Hsieh JT, Wu HC, et al. Epidermal growth factor receptor-mediated autocrine and paracrine stimulation of human transitional cell carcinoma. Cancer Res 1993;53:5300-7.
5. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000;5:3-10.
6. Ferrara N. VEGF and the quest for tumor angiogenesis factors. Nat Rev Cancer 2002;2:795-803.
7. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
8. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci 2003;28:488-94.
9. Banerjee SN, Sengupta K, Banerjee S, Saxena NK, Banerjee SK. 2-Methoxyestradiol exhibits a biphasic effect on VEGF-A in tumor cells and upregulation is mediated through ER-α, a possible signaling pathway associated with the impact of 2-ME2 on proliferative cells. Neoplasia 2003;5:417-26.
10. Mercurio AM, Bachelder RE, Bates RC, Chung J. Autocrine signaling in carcinoma: VEGF and the α 6 β 4 integrin. Semin Cancer Biol 2004;14:115-22.
11. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000;11:279-303.
12. Chakraborty G, Jain S, Behera R, et al. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 2006;6:819-30.
13. Wai PY, Kuo PC. The role of osteopontin in tumor metastasis. J Surg Res 2004;121:228-41.
14. Jain S, Chakraborty G, Kundu GC. The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C α/c-Src/IκB kinase α/β-dependent prostate tumor progression and angiogenesis. Cancer Res 2006;66:6638-48.
15. Philip S, Bulbule A, Kundu GC. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-κ B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 2001;276:44926-35.
16. Das R, Mahabeleshwar GH, Kundu GC. Osteopontin stimulates cell motility and nuclear factor κB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 2003;278:28593-606.
17. Rangaswami H, Bulbule A, Kundu GC. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/I κ B α kinase-dependent nuclear factor κ B-mediated promatrix metalloproteinase-9 activation. J Biol Chem 2004;279:38921-35.
18. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006;16:79-87.
19. Rittling SR, Chen Y, Feng F, Wu Y. Tumor-derived osteopontin is soluble, not matrix associated. J Biol Chem 2002;277:9175-82.
20. Senger DR, Perruzzi CA, Papadopoulos A, Tenen DG. Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. Biochim Biophys Acta 1989;996:43-8.
21. Denhardt DT, Mistretta D, Chambers AF, et al. Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin Exp Metastasis 2003;20:77-84.
22. Zhang P, Ostrander JH, Faivre EJ, Olsen A, Fitzsimmons D, Lange CA. Regulated association of protein kinase B/Akt with breast tumor kinase. J Biol Chem 2005;280:1982-91.
23. Chen HY, Shen CH, Tsai YT, Lin FC, Huang YP, Chen RH. Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin. Mol Cell Biol 2004;24:10558-72.
24. Harvey AJ, Crompton MR. Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation. Oncogene 2003;22:5006-10.
25. Roybal CN, Yang S, Sun CW, et al. Homocysteine increases the expression of vascular endothelial growth factor by a mechanism involving endoplasmic reticulum stress and transcription factor ATF4. J Biol Chem 2004;279:14844-52.
26. Roybal CN, Hunsaker LA, Barbash O, Vander Jagt DL, Abcouwer SF. The oxidative stressor arsenite activates vascular endothelial growth factor mRNA transcription by an ATF4-dependent mechanism. J Biol Chem 2005;280:20331-9.
27. He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent semaphorin III. Cell 1997;90:739-51.
28. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD. Neuropilin is a semaphorin III receptor. Cell 1997;90:753-62.
29. Soker S, Fidder H, Neufeld G, Klagsbrun M. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem 1996;271:5761-7.
30. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735-45.
31. Miao HQ, Lee P, Lin H, Soker S, Klagsbrun M. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J 2000;14:2532-9.
32. Barr MP, Byrne AM, Duffy AM, et al. A peptide corresponding to the neuropilin-1-binding site on VEGF (165) induces apoptosis of neuropilin-1-expressing breast tumour cells. Br J Cancer 2005;92:328-33.
33. Leopold JA, Walker J, Scribner AW, et al. Glucose-6-phosphate dehydrogenase modulates vascular endothelial growth factor-mediated angiogenesis. J Biol Chem 2003;278:32100-6.
34. Sweeney CJ, Mehrotra S, Sadaria MR, et al. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther 2005;4:1004-12.
35. Chakraborty G, Rangaswami H, Jain S, Kundu GC. Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis. J Biol Chem 2006;281:11322-31.
36. Bachelder RE, Crago A, Chung J, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001;61:5736-40.
37. Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE 2001;RE 21:1-17.
38. Bachelder RE, Lipscomb EA, Lin X, et al. Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer Res 2003;63:5230-3.
39. Wang L, Zeng H, Wang P, Soker S, Mukhopadhyay D. Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J Biol Chem 2003;278:48848-60.
40. Takahashi F, Akutagawa S, Fukumoto H, et al. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer 2002;98:707-12.
41. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi CA, Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the αvβ3 integrin, osteopontin, and thrombin. Am J Pathol 1996;149:293-305.
42. Shijubo N, Uede T, Kon S, et al. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 1999;160:1269-73.
43. Shijubo N, Uede T, Kon S, Nagata M, Abe S. Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncog 2000;11:135-46.
44. Giavazzi R, Nicoletti MI. Small molecules in anti-angiogenic therapy. Curr Opin Invest Drugs 2002;3:482-91.
45. Kerbel RS, Viloria-Petit A, Klement G, Rak J. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000;36:1248-57.
46. Jain S, Chakraborty G, Bulbule A, Kaur R, Kundu GC. Osteopontin: an emerging therapeutic target for anti-cancer therapy. Expert Opin Ther Targets 2007;11:81-90.